A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

Resistance to next-generation anti-androgen enzalutamide (ENZ) constitutes a major challenge for the treatment of castration-resistant prostate cancer (CRPC). By performing genome-wide ChIP-seq profiling in ENZ-resistant CRPC cells we identify a set of androgen receptor (AR) binding sites with incre...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yundong, Wei, Ting, Ye, Zhenqing, Orme, Jacob J., Lin, Dong, Sheng, Haoyue, Fazli, Ladan, Jeffrey Karnes, R., Jimenez, Rafael, Wang, Liguo, Wang, Liewei, Gleave, Martin E., Wang, Yuzhuo, Shi, Lei, Huang, Haojie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943793/
https://www.ncbi.nlm.nih.gov/pubmed/33750801
http://dx.doi.org/10.1038/s41467-021-21860-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943793/
https://www.ncbi.nlm.nih.gov/pubmed/33750801
http://dx.doi.org/10.1038/s41467-021-21860-7

Ejemplares similares